Skip to main content

Table 2 Developmental status of pattern recognition receptor antagonists for potential use as therapeutics

From: Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease

Compound Target Drug class Indications Company Clinical phase
NI-0101 TLR4 Antibody RA Novimmune Phase I
Chaperonin 10/X Toll TLR4 Protein RA, psoriasis, MS Cbio Ltd Phase II
VTX-763 TLR8 Small molecule Autoimmune disorders VentiRx Pharmaceuticals Pre-clinical
CRID3 NLRP3 Small molecule   Amgen Pre-clinical
OPN-305 TLR2 Antibody Ischaemia reperfusion injury Opsona Therapeutics Phase I
IMO-3100 TLR7/TLR9 DNA-based small molecule Psoriasis Idera pharmaceuticals Phase II
DV1179 TLR7/TLR9 Small molecule SLE Dynavax Phase II
CPG52364 TLR7/TLR9 Small molecule SLE Pfizer Phase II
  1. MS, multiple sclerosis; NLR, nucleotide-binding oligomerization domain-like receptor; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TLR, Toll-like receptor.